A neurobiological basis for substance abuse comorbidity in schizophrenia.
It is commonly held that substance use comorbidity in schizophrenia represents self-medication, an attempt by patients to alleviate adverse positive and negative symptoms, cognitive impairment, or medication side effects. However, recent advances suggest that increased vulnerability to addictive behavior may reflect the impact of the neuropathology of schizophrenia on the neural circuitry mediating drug reward and reinforcement. We hypothesize that abnormalities in the hippocampal formation and frontal cortex facilitate the positive reinforcing effects of drug reward and reduce inhibitory control over drug-seeking behavior. In this model, disturbances in drug reward are mediated, in part, by dysregulated neural integration of dopamine and glutamate signaling in the nucleus accumbens resulting form frontal cortical and hippocampal dysfunction. Altered integration of these signals would produce neural and motivational changes similar to long-term substance abuse but without the necessity of prior drug exposure. Thus, schizophrenic patients may have a predilection for addictive behavior as a primary disease symptom in parallel to, and in many, cases independent from, their other symptoms.
Chambers
R A
RA
Ribicoff Research Facilities, West Haven Veterans Administration Hospital, Connecticut, USA.
Krystal
J H
JH
Self
D W
DW
D000818:Animals; D004198:Disease Susceptibility; D004298:Dopamine / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism / Q000473:pathology; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D009446:Neurobiology; D009714:Nucleus Accumbens / Q000378:metabolism / Q000473:pathology; D012559:Schizophrenia / Q000150:complications* / Q000378:metabolism / Q000473:pathology; D012565:Schizophrenic Psychology; D019966:Substance-Related Disorders / Q000150:complications*
D004298:Dopamine